Revenue climbs at Jazz Pharmaceuticals (NASDAQ: JAZZ) but 2025 GAAP loss emerges
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Jazz Pharmaceuticals reported record 2025 total revenues of $4.27 billion, up 5%, with fourth-quarter revenue of $1.20 billion, up 10% year over year. Growth was driven by neuroscience and oncology franchises.
Flagship sleep drug Xywav generated $1.66 billion in 2025 sales, up 12%, while Epidiolex/Epidyolex reached $1.06 billion, up 9%. Oncology net product sales were $1.13 billion, up 2%, including launches of Modeyso and Ziihera.
Despite strong revenue, Jazz posted a 2025 GAAP net loss of $356 million, compared with $560 million net income in 2024, primarily due to $948 million of acquired in‑process R&D and litigation settlements. Non‑GAAP adjusted net income was $522 million. The company generated $1.36 billion of operating cash flow and guided 2026 revenue to $4.25–$4.50 billion.
Positive
- None.
Negative
- 2025 GAAP profitability deterioration: GAAP net income fell from a $560 million profit in 2024 to a $356 million loss in 2025, driven by $947.9 million of acquired in‑process R&D and sizeable litigation settlements within SG&A.
Insights
Jazz shows solid top-line growth but a GAAP loss from heavy R&D and legal costs.
Jazz Pharmaceuticals delivered
Profitability was pressured by strategic spending. GAAP results swung to a
On a non-GAAP basis, adjusted net income was
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File No.) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
011-353 -1 -634-7800
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 24, 2026, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the full year and fourth quarter ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this current report.
The information in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits | ||||
| Exhibit Number | Description | ||||
| 99.1 | Press Release dated February 24, 2026. | ||||
| 104 | 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY | ||||||||
| By: | /s/ Philip L. Johnson | |||||||
| Name: | Philip L. Johnson | |||||||
| Title: | Executive Vice President and Chief Financial Officer | |||||||
Date: February 24, 2026
Exhibit 99.1
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 –
– Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA –
– Xywav® achieved $1.7 billion in revenue and 12% YoY growth in 2025 –
– Epidiolex® achieved $1.1 billion in revenue and 9% YoY growth in 2025 –
– Strong Modeyso™ launch with $37 million in revenue in first full quarter on market –
– Expect 2026 total revenues of $4.25 to $4.50 billion –
DUBLIN, February 24, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026.
“2025 was an exceptional year for Jazz, representing our 21st consecutive year of top-line growth and underscoring our commitment to operational excellence as we deliver meaningful innovation for patients,” said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. “In the fourth quarter, our disciplined execution resulted in $1.2 billion in revenue, reflecting 10% year-over-year growth and our highest revenue quarter ever. This performance provides us with strong momentum into 2026, as we prepare for the potential launch of zanidatamab in GEA, sustain launch execution for Modeyso and Zepzelca®, and reinforce the differentiated profiles of Epidiolex and Xywav as the leading branded treatments for epilepsy and narcolepsy, respectively. In parallel, we continue to advance our pipeline and pursue a corporate development strategy aligned with our rare disease focus that supports durable growth and long-term value creation for patients and shareholders.”
“Jazz had a transformative year across our R&D pipeline, led by the HERIZON-GEA-01 data, which we believe firmly positions zanidatamab as the HER2-targeted agent of choice, with the potential to reshape first-line treatment for HER2+ metastatic GEA patients,” said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. “We expect to build on this progress in 2026, as these results not only highlight zanidatamab’s potential to help patients with GEA, but also de-risk our clinical trials in additional indications, including HER2+ metastatic breast cancer.”
Key 2025 Highlights
•Total revenues in 2025 grew to $4.3 billion (+5% year-over-year (YoY)), generating $1.4 billion in cash from operations.
•Research & Development:
◦Practice-changing Phase 3 HERIZON-GEA-01 results support zanidatamab as the HER2-targeted agent of choice in HER2+ 1L gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status.
◦Multiple registrational trials of zanidatamab are underway, including in metastatic breast cancer (mBC), supporting a broad development program designed to maximize patient impact and long-term shareholder value.
1
•Commercial:
◦Continued leadership in rare sleep with Xywav net product sales increasing to $1.7 billion (+12% YoY) and total sleep franchise1 revenues exceeding $2 billion in 2025.
◦Epidiolex/Epidyolex® generated more than $1 billion in 2025 net product sales (+9% YoY).
◦Completed acquisition of Chimerix Inc., secured FDA approval for and successfully launched Modeyso (dordaviprone) in H3 K27M-mutant diffuse midline glioma, achieving $48 million in sales since launch in August 2025.
◦Received FDA approval and launched Zepzelca, in combination with atezolizumab, for first-line maintenance treatment of extensive-stage small cell lung cancer.
•Company expects 2026 total revenue of between $4.25 and $4.50 billion, with double-digit growth across the combined epilepsy and oncology franchises, and Xywav revenue flat to up mid-single digits.
•Tom Riga was named chief business officer to accelerate corporate development efforts across rare disease.
Business Updates
Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution:
•Xywav net product sales increased 12% to $1.7 billion in 2025 and increased 16% to $465 million in 4Q25 compared to the same periods in 2024.
•Strong new patient growth continued, with approximately 500 net patient adds in 4Q25. There were approximately 16,175 active patients exiting the quarter, comprised of approximately 10,950 narcolepsy patients and approximately 5,225 idiopathic hypersomnia (IH) patients.
Epidiolex/Epidyolex (cannabidiol):
•Epidiolex/Epidyolex achieved blockbuster status in 2025 with net product sales increasing 9% to $1.1 billion in 2025 and increasing 4% to $287 million in 4Q25 compared to the same periods in 2024.
Ziihera® (zanidatamab-hrii):
•Ziihera net product sales in biliary tract cancer (BTC) were $25 million in 2025 and $9 million in 4Q25 following product launch in December 2024.
•Expect to complete supplemental biologics license application (sBLA) submission under Real Time Oncology Review (RTOR) in 1Q26 with potential launch in 1L HER2+ GEA in 2H26.
•FDA granted Breakthrough Therapy designation (BTD) for zanidatamab's development for patients with HER2+ unresectable locally advanced or metastatic GEA.
•Submitted HERIZON-GEA-01 data for potential inclusion in National Comprehensive Cancer Network (NCCN) guidelines.
•EmpowHER-BC-303 trial in mBC patients previously treated with, or intolerant to, trastuzumab deruxtecan on track to complete enrollment in 1H27, with top-line results expected in late 2027 or early 2028.
Modeyso (dordaviprone):
•Following product launch in August 2025, Modeyso net product sales were $48 million in 2025 and $37 million in 4Q25.
•The Company sold its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $200 million (50% to Jazz).
1 Rare sleep franchise consists of Xywav, Xyrem® and high-sodium oxybate authorized generic (AG) royalties.
2
Zepzelca (lurbinectedin):
•Zepzelca net product sales decreased 4% to $307 million in 2025 and increased 15% to $90 million in 4Q25 compared to the same periods in 2024.
Financial Highlights
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| (In thousands, except per share amounts) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Total revenues | $ | 1,197,926 | $ | 1,088,173 | $ | 4,267,586 | $ | 4,068,950 | |||||||||||||||
| GAAP net income (loss) | $ | 203,451 | $ | 191,115 | $ | (356,148) | $ | 560,120 | |||||||||||||||
Non-GAAP adjusted net income1 | $ | 420,888 | $ | 400,525 | $ | 521,924 | $ | 1,351,970 | |||||||||||||||
| GAAP earnings (loss) per share | $ | 3.21 | $ | 3.11 | $ | (5.84) | $ | 8.65 | |||||||||||||||
Non-GAAP adjusted earnings per share1 | $ | 6.64 | $ | 6.51 | $ | 8.38 | $ | 20.65 | |||||||||||||||
____________________________
1.Commencing with the first quarter of 2025, we are no longer including an adjustment for non-cash interest expense in the Company's non-GAAP adjusted financial measures and for the purposes of comparability, non-GAAP adjusted financial measures for the 2024 periods have been updated to reflect this change. See “Non-GAAP Financial Measures” below.
Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.
Total Revenues
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| (In thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Xywav | $ | 465,451 | $ | 400,964 | $ | 1,656,986 | $ | 1,473,202 | |||||||||||||||
| Xyrem | 37,781 | 49,290 | 146,034 | 233,816 | |||||||||||||||||||
| Epidiolex/Epidyolex | 287,122 | 275,047 | 1,059,197 | 972,423 | |||||||||||||||||||
| Sativex | 1,503 | 5,173 | 16,277 | 18,877 | |||||||||||||||||||
| Total Neuroscience | 791,857 | 730,474 | 2,878,494 | 2,698,318 | |||||||||||||||||||
| Rylaze/Enrylaze | 108,160 | 101,487 | 402,920 | 410,846 | |||||||||||||||||||
| Zepzelca | 90,440 | 78,328 | 307,309 | 320,318 | |||||||||||||||||||
| Defitelio/defibrotide | 58,872 | 57,650 | 199,392 | 216,565 | |||||||||||||||||||
| Vyxeos | 34,731 | 53,247 | 146,709 | 162,595 | |||||||||||||||||||
| Modeyso | 36,541 | — | 48,043 | — | |||||||||||||||||||
| Ziihera | 8,538 | 1,051 | 24,810 | 1,051 | |||||||||||||||||||
| Total Oncology | 337,282 | 291,763 | 1,129,183 | 1,111,375 | |||||||||||||||||||
| Other | 3,309 | 2,974 | 14,172 | 11,471 | |||||||||||||||||||
| Product sales, net | 1,132,448 | 1,025,211 | 4,021,849 | 3,821,164 | |||||||||||||||||||
| High-sodium oxybate AG royalty revenue | 55,696 | 55,307 | 211,725 | 217,575 | |||||||||||||||||||
| Other royalty and contract revenues | 9,782 | 7,655 | 34,012 | 30,211 | |||||||||||||||||||
| Total revenues | $ | 1,197,926 | $ | 1,088,173 | $ | 4,267,586 | $ | 4,068,950 | |||||||||||||||
3
Total revenues increased 5% in 2025 and 10% in 4Q25 compared to the same periods in 2024.
Total neuroscience revenue, including high-sodium oxybate AG royalty revenue, was $3.1 billion in 2025, an increase of 6% compared to $2.9 billion in 2024, and $848 million in 4Q25, an increase of 8% compared to $786 million in 4Q24. The increase in both periods was primarily due to higher Xywav and Epidiolex/Epidyolex net product sales, partially offset by decreased Xyrem net product sales.
Oncology net product sales were $1.1 billion in 2025, an increase of 2% compared to 2024, and $337 million in 4Q25, an increase of 16% compared to $292 million in 4Q24, primarily due to the inclusion of Modeyso and Ziihera net product sales in both periods. The increase in 4Q25 also included higher Zepzelca net product sales, partially offset by decreased Vyxeos® net product sales.
Operating Expenses and Income Tax (Benefit) Expense
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| (In thousands, except percentages) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| GAAP: | |||||||||||||||||||||||
| Cost of product sales | $ | 153,528 | $ | 128,713 | $ | 503,296 | $ | 445,713 | |||||||||||||||
| Gross margin on product sales, net | 86.4% | 87.4% | 87.5% | 88.3% | |||||||||||||||||||
| Selling, general and administrative | $ | 406,212 | $ | 369,287 | $ | 1,809,271 | $ | 1,385,294 | |||||||||||||||
| % of total revenues | 33.9% | 33.9% | 42.4% | 34.0% | |||||||||||||||||||
| Research and development | $ | 213,909 | $ | 240,500 | $ | 782,736 | $ | 884,000 | |||||||||||||||
| % of total revenues | 17.9% | 22.1% | 18.3% | 21.7% | |||||||||||||||||||
| Acquired in-process research and development | $ | — | $ | — | $ | 947,862 | $ | 10,000 | |||||||||||||||
| Income tax (benefit) expense | $ | 4,963 | $ | (57,912) | $ | (272,443) | $ | (91,429) | |||||||||||||||
| Effective tax rate | 2.4% | (43.5)% | 43.4% | (19.4)% | |||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| (In thousands, except percentages) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Non-GAAP adjusted: | |||||||||||||||||||||||
| Cost of product sales | $ | 106,841 | $ | 86,492 | $ | 336,016 | $ | 295,897 | |||||||||||||||
| Gross margin on product sales, net | 90.6% | 91.6% | 91.6% | 92.3% | |||||||||||||||||||
| Selling, general and administrative | $ | 360,533 | $ | 323,167 | $ | 1,603,255 | $ | 1,226,724 | |||||||||||||||
| % of total revenues | 30.1% | 29.7% | 37.6% | 30.1% | |||||||||||||||||||
| Research and development | $ | 189,915 | $ | 220,857 | $ | 686,645 | $ | 809,327 | |||||||||||||||
| % of total revenues | 15.9% | 20.3% | 16.1% | 19.9% | |||||||||||||||||||
| Acquired in-process research and development | $ | — | $ | — | $ | 947,862 | $ | 10,000 | |||||||||||||||
| Income tax (benefit) expense | $ | 73,628 | $ | (435) | $ | (26,467) | $ | 127,093 | |||||||||||||||
| Effective tax rate | 14.9% | (0.1)% | (5.3)% | 8.6% | |||||||||||||||||||
Changes in operating expenses and income tax (benefit) expense in 2025 and 4Q25 over the prior year periods are primarily due to the following:
•Cost of product sales, on a GAAP and non-GAAP adjusted basis, increased in 2025 compared to 2024, primarily due to changes in product mix. Cost of product sales, on a GAAP basis, in 2025 included higher acquisition accounting inventory fair value step up expense compared to 2024. Cost of product sales, on a GAAP and non-GAAP adjusted basis, increased in 4Q25 compared to 4Q24, primarily due to changes in product mix, partially offset by lower inventory provisions.
•Selling, general and administrative (SG&A) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2025 compared to 2024, primarily due to Xyrem antitrust litigation settlements of
4
$234 million, the Avadel litigation settlement of $90 million and higher compensation-related expenses. SG&A expenses, on a GAAP and non-GAAP adjusted basis, increased in 4Q25 compared to 4Q24, primarily due to higher compensation-related expenses.
•Research and development (R&D) expenses, on a GAAP and non-GAAP adjusted basis, decreased in 2025 and 4Q25, compared to the same periods in 2024, primarily due to lower clinical study costs primarily related to zanidatamab as a result of timing of clinical trial activities, JZP385 (essential tremor) following discontinuation of this program, and JZP258 (XYLO/DUET) due to the completion of these trials in the first half of 2025, partially offset by the addition of costs relating to Modeyso and increased personnel costs following the acquisition of Chimerix.
•Acquired in-process research and development (IPR&D) in 2025, on a GAAP and non-GAAP adjusted basis, represents the value allocated to Modeyso in the Chimerix Acquisition of $905 million and the upfront payment made in connection with our global license agreement with Saniona of $43 million.
•Income tax benefit in 2025, on a GAAP and non-GAAP adjusted basis, included a benefit of $213 million on recognition of certain U.S. federal and state deferred tax assets acquired through the Chimerix acquisition. Income tax benefit, on a GAAP and non-GAAP adjusted basis, in 4Q24 was primarily due to patent box benefits recognized.
Cash Flow and Balance Sheet
As of December 31, 2025, cash, cash equivalents and investments were $2.4 billion, and the outstanding principal balance of the Company’s long-term debt was $5.4 billion. In addition, the Company had undrawn borrowing capacity under a revolving credit facility of $885 million. For the year ended December 31, 2025, the Company generated $1.4 billion of cash from operations reflecting strong business performance and continued financial discipline.
2026 Financial Guidance
Jazz Pharmaceutical's full year 2026 financial guidance is as follows:
| (In millions) | Guidance | ||||
| Total Revenues | $4,250 - $4,500 | ||||
| (In millions, except percentages) | GAAP | Non-GAAP | |||||||||
| Gross margin % | 89% - 90% | 90% - 91%1 | |||||||||
| SG&A expenses | $1,424 - $1,497 | $1,260 - $1,3201 | |||||||||
| R&D expenses | $811 - $867 | $725 - $7751 | |||||||||
| Effective tax rate | 0% - 10% | 11.5% - 13.5%1 | |||||||||
Weighted-average ordinary shares outstanding2 | 65 - 66 | 65 - 66 | |||||||||
___________________________
1.See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included in the table titled "Reconciliation of 2026 GAAP to Non-GAAP Guidance Measures".
2.Assumes inclusion of shares outstanding in relation to the 2.000% exchangeable senior notes due 2026, or the 2026 Notes, and the 3.125% exchangeable senior notes due 2030, or the 2030 Notes, which we refer to collectively as the Exchangeable Senior Notes, given the Company's share price exceeds the conversion prices of the Exchangeable Senior Notes.
Conference Call Details
Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. ET (9:30 p.m. GMT) to provide a business and financial update and discuss its 2025 full year and 4Q25 results and 2026 guidance.
5
Interested parties may register for the call here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Non-GAAP Financial Measures
To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this press release and the accompanying tables. In particular, the Company presents non-GAAP adjusted net income (and the related per share measure) and its line-item components, as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP adjusted net income (and the related per share measure) and its line-item components exclude from GAAP reported net income (loss) (and the related per share measure) and its line-item components certain items, as detailed in the reconciliation tables that follow, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of the non-GAAP adjustments. In this regard, the components of non-GAAP adjusted net income, including non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure.
The Company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the Company’s financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare the Company’s results from period to period, to its forward-looking guidance, and to identify operating trends in the Company’s business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the Company’s financial performance. Jazz Pharmaceuticals’ management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the Company’s business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals’ management, the Company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the Company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under
6
any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. In this regard, commencing with the first quarter of 2025, the Company is no longer including an adjustment for non-cash interest expense in the Company's non-GAAP adjusted financial measures. For purposes of comparability, non-GAAP adjusted financial measures for the 2024 periods have been updated to reflect this change. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, including the Company’s 2026 financial guidance and the Company’s expectations related thereto, including with respect to anticipated catalysts; anticipated multiple near-term pipeline catalysts that each represent significant opportunities to drive greater revenue and create long-term value; the Company’s advancement of pipeline programs and the timing of development activities, regulatory activities, approvals, and submissions related thereto, including the timing of the completion of the submission of the sBLA for, and launch and approval of, zanidatamab in 1L GEA; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof; and the Company’s development, regulatory and commercialization strategy; the Company’s expectations with respect to its products and product candidates and the potential of the Company’s products and product candidates and the potential regulatory path related thereto; including zanidatamab's potential to be the HER2-targeted agent of choice in HER2+ 1L GEA, regardless of PD-L1 status, and to reshape first-line treatment for HER2+ metastatic GEA patients; the Company’s capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; the Company’s ability to realize the commercial potential of its products; the Company’s net product sales and goals for net product sales from new and acquired products; the Company’s views and expectations relating to its patent portfolio, including with respect to expected patent protection, as well as expectations with respect to exclusivity; the Company’s clinical trials confirming clinical benefit or enabling regulatory submissions, including the potential of the ongoing Phase 3 ACTION trial to confirm clinical benefit of Modeyso in recurrent H3 K27M-mutant diffuse glioma and extend to use in first-line patients; and other statements that are not historical facts. These forward-looking statements are based on the Company’s current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.
Actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Epidiolex/Epidyolex, Ziihera, Modeyso, Zepzelca and other lead marketed products; effectively launching and commercializing the Company’s other products and product candidates; the successful completion of development and regulatory activities with respect to the Company’s product candidates; obtaining and maintaining adequate coverage and reimbursement for the Company’s products; the time-consuming and uncertain regulatory approval process, including the risk that the Company’s current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all, including the risk that the Company’s sBLA submission for zanidatamab in 1L GEA may not be completed or, if completed, approved in a timely manner or at all; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and
7
assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the Company’s business operations and financial results; protecting and enhancing the Company’s intellectual property rights and the Company’s commercial success being dependent upon the Company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the Company’s products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired products, product candidates and businesses; the Company’s ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the Company’s cash flows and capital resources; the Company’s ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the Company’s ability to meet its projected long-term goals and objectives, in the time periods that the Company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the Company’s long-term goals and objectives; fluctuations in the market price and trading volume of the Company's ordinary shares; and other risks and uncertainties affecting the Company, including those described from time to time under the caption “Risk Factors” and elsewhere in the Company’s Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and future filings and reports by the Company. Other risks and uncertainties of which the Company is not currently aware may also affect the Company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.
8
JAZZ PHARMACEUTICALS PLC
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
(In thousands, except per share amounts)
(Unaudited)
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Product sales, net | $ | 1,132,448 | $ | 1,025,211 | $ | 4,021,849 | $ | 3,821,164 | |||||||||||||||
| Royalties and contract revenues | 65,478 | 62,962 | 245,737 | 247,786 | |||||||||||||||||||
| Total revenues | 1,197,926 | 1,088,173 | 4,267,586 | 4,068,950 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Cost of product sales (excluding amortization of acquired developed technologies) | 153,528 | 128,713 | 503,296 | 445,713 | |||||||||||||||||||
| Selling, general and administrative | 406,212 | 369,287 | 1,809,271 | 1,385,294 | |||||||||||||||||||
| Research and development | 213,909 | 240,500 | 782,736 | 884,000 | |||||||||||||||||||
| Intangible asset amortization | 169,742 | 158,903 | 654,661 | 627,313 | |||||||||||||||||||
| Acquired in-process research and development | — | — | 947,862 | 10,000 | |||||||||||||||||||
| Total operating expenses | 943,391 | 897,403 | 4,697,826 | 3,352,320 | |||||||||||||||||||
| Income (loss) from operations | 254,535 | 190,770 | (430,240) | 716,630 | |||||||||||||||||||
| Interest expense, net | (45,406) | (51,256) | (195,051) | (238,097) | |||||||||||||||||||
| Foreign exchange loss | (658) | (6,295) | (2,568) | (8,182) | |||||||||||||||||||
| Income (loss) before income tax expense (benefit) and equity in loss of investees | 208,471 | 133,219 | (627,859) | 470,351 | |||||||||||||||||||
| Income tax expense (benefit) | 4,963 | (57,912) | (272,443) | (91,429) | |||||||||||||||||||
| Equity in loss of investees | 57 | 16 | 732 | 1,660 | |||||||||||||||||||
| Net income (loss) | $ | 203,451 | $ | 191,115 | $ | (356,148) | $ | 560,120 | |||||||||||||||
| Net income (loss) per ordinary share: | |||||||||||||||||||||||
| Basic | $ | 3.33 | $ | 3.16 | $ | (5.84) | $ | 9.06 | |||||||||||||||
| Diluted | $ | 3.21 | $ | 3.11 | $ | (5.84) | $ | 8.65 | |||||||||||||||
| Weighted-average ordinary shares used in per share calculations - basic | 61,058 | 60,538 | 60,981 | 61,838 | |||||||||||||||||||
| Weighted-average ordinary shares used in per share calculations - diluted | 63,433 | 61,503 | 60,981 | 66,007 | |||||||||||||||||||
9
JAZZ PHARMACEUTICALS PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
| December 31, 2025 | December 31, 2024 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 1,391,899 | $ | 2,412,864 | |||||||
| Investments | 1,050,000 | 580,000 | |||||||||
| Accounts receivable, net of allowances | 830,747 | 716,765 | |||||||||
| Inventories | 416,962 | 480,445 | |||||||||
| Prepaid expenses | 152,481 | 177,411 | |||||||||
| Other current assets | 323,954 | 261,543 | |||||||||
| Total current assets | 4,166,043 | 4,629,028 | |||||||||
| Property, plant and equipment, net | 199,857 | 173,413 | |||||||||
| Operating lease assets | 58,880 | 53,582 | |||||||||
| Intangible assets, net | 4,429,510 | 4,755,695 | |||||||||
| Goodwill | 1,829,340 | 1,716,323 | |||||||||
| Deferred tax assets, net | 869,130 | 560,245 | |||||||||
| Deferred financing costs | 7,550 | 9,489 | |||||||||
| Other non-current assets | 99,030 | 114,482 | |||||||||
| Total assets | $ | 11,659,340 | $ | 12,012,257 | |||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 122,061 | $ | 77,869 | |||||||
| Accrued liabilities | 1,034,170 | 910,947 | |||||||||
| Current portion of long-term debt | 1,029,903 | 31,000 | |||||||||
| Income taxes payable | 56,387 | 18,757 | |||||||||
| Total current liabilities | 2,242,521 | 1,038,573 | |||||||||
| Long-term debt, less current portion | 4,328,354 | 6,077,640 | |||||||||
| Operating lease liabilities, less current portion | 50,892 | 38,938 | |||||||||
| Deferred tax liabilities, net | 594,470 | 676,736 | |||||||||
| Other non-current liabilities | 124,519 | 86,614 | |||||||||
| Total shareholders’ equity | 4,318,584 | 4,093,756 | |||||||||
| Total liabilities and shareholders’ equity | $ | 11,659,340 | $ | 12,012,257 | |||||||
JAZZ PHARMACEUTICALS PLC
SUMMARY OF CASH FLOWS
(In thousands)
(Unaudited)
| Year Ended December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Net cash provided by operating activities | $ | 1,355,773 | $ | 1,395,908 | |||||||
| Net cash used in investing activities | (1,509,913) | (508,195) | |||||||||
| Net cash provided by (used in) financing activities | (873,380) | 20,516 | |||||||||
| Effect of exchange rates on cash and cash equivalents | 6,555 | (1,675) | |||||||||
| Net increase (decrease) in cash and cash equivalents | $ | (1,020,965) | $ | 906,554 | |||||||
10
JAZZ PHARMACEUTICALS PLC
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
(In thousands, except per share amounts)
(Unaudited)
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| Net Income | Diluted Earnings Per Share (EPS) | Net Income | Diluted EPS | Net Income (Loss) | Diluted EPS/(Loss) Per Share (LPS) | Net Income | Diluted EPS1 | ||||||||||||||||||||||||||||||||||||||||
| GAAP reported | $ | 203,451 | $ | 3.21 | $ | 191,115 | $ | 3.11 | $ | (356,148) | $ | (5.84) | $ | 560,120 | $ | 8.65 | |||||||||||||||||||||||||||||||
| Intangible asset amortization | 169,742 | 2.68 | 158,903 | 2.58 | 654,661 | 10.51 | 627,313 | 9.50 | |||||||||||||||||||||||||||||||||||||||
| Share-based compensation expense | 70,854 | 1.12 | 70,190 | 1.14 | 291,133 | 4.67 | 248,045 | 3.76 | |||||||||||||||||||||||||||||||||||||||
| Acquisition accounting inventory fair value step-up | 40,604 | 0.64 | 37,794 | 0.61 | 147,948 | 2.38 | 135,014 | 2.05 | |||||||||||||||||||||||||||||||||||||||
Integration related expenses2 | 4,902 | 0.08 | — | — | 30,306 | 0.49 | — | — | |||||||||||||||||||||||||||||||||||||||
| Income tax effect of above adjustments | (68,665) | (1.09) | (57,477) | (0.93) | (245,976) | (3.95) | (218,522) | (3.31) | |||||||||||||||||||||||||||||||||||||||
| Effect of potentially dilutive ordinary shares on non-GAAP adjusted EPS | — | — | — | — | — | 0.12 | — | — | |||||||||||||||||||||||||||||||||||||||
| Non-GAAP adjusted | $ | 420,888 | $ | 6.64 | $ | 400,525 | $ | 6.51 | $ | 521,924 | $ | 8.38 | $ | 1,351,970 | $ | 20.65 | |||||||||||||||||||||||||||||||
Weighted-average ordinary shares used in diluted per share calculations - GAAP1 | 63,433 | 61,503 | 60,981 | 66,007 | |||||||||||||||||||||||||||||||||||||||||||
| Dilutive effect of employee equity incentive and purchase plans | — | — | 1,304 | — | |||||||||||||||||||||||||||||||||||||||||||
| Dilutive effect of the 2030 Notes | — | — | 3 | — | |||||||||||||||||||||||||||||||||||||||||||
Weighted-average ordinary shares used in diluted per share calculations - non-GAAP1 | 63,433 | 61,503 | 62,288 | 66,007 | |||||||||||||||||||||||||||||||||||||||||||
________________________________________________
Explanation of Adjustments and Certain Line Items:
1.Diluted EPS was calculated using the "if-converted" method in relation to the 2026 Notes. In July 2024, we made the irrevocable election to net share settle the 2026 Notes. As a result, the assumed issuance of ordinary shares upon exchange of the 2026 Notes has only been included in the calculation of diluted EPS, on a GAAP and non-GAAP adjusted basis, up to the date the irrevocable election was made. Net income per diluted share, on a GAAP and on a non-GAAP adjusted basis, for the year ended December 31, 2024, included 3.5 million shares related to the assumed conversion of the 2026 Notes and the associated interest expense, net of tax, add-back to GAAP reported net income and non-GAAP adjusted net income of $11 million.
2.Integration related expenses with respect to the Chimerix acquisition.
11
JAZZ PHARMACEUTICALS PLC
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION - CERTAIN LINE ITEMS
(In thousands, except percentages)
(Unaudited)
| Three months ended December 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||
| Cost of product sales | Gross margin | SG&A | R&D | Intangible asset amortization | Interest expense, net | Income tax expense | Effective tax rate | ||||||||||||||||||||||||||||||||||||||||
| GAAP Reported | $ | 153,528 | 86.4 | % | $ | 406,212 | $ | 213,909 | $ | 169,742 | $ | 45,406 | $ | 4,963 | 2.4 | % | |||||||||||||||||||||||||||||||
| Non-GAAP Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||
| Intangible asset amortization | — | — | — | — | (169,742) | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Share-based compensation expense | (5,068) | 0.5 | (42,654) | (23,132) | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Acquisition accounting inventory fair value step-up | (40,604) | 3.7 | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Integration related expenses | (1,015) | — | (3,025) | (862) | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Income tax effect of above adjustments | — | — | — | — | — | — | 68,665 | 12.5 | |||||||||||||||||||||||||||||||||||||||
| Total of non-GAAP adjustments | (46,687) | 4.2 | (45,679) | (23,994) | (169,742) | — | 68,665 | 12.5 | |||||||||||||||||||||||||||||||||||||||
| Non-GAAP Adjusted | $ | 106,841 | 90.6 | % | $ | 360,533 | $ | 189,915 | $ | — | $ | 45,406 | $ | 73,628 | 14.9 | % | |||||||||||||||||||||||||||||||
| Three months ended December 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||
| Cost of product sales | Gross margin | SG&A | R&D | Intangible asset amortization | Interest expense, net | Income tax benefit | Effective tax rate | ||||||||||||||||||||||||||||||||||||||||
| GAAP Reported | $ | 128,713 | 87.4 | % | $ | 369,287 | $ | 240,500 | $ | 158,903 | $ | 51,256 | $ | (57,912) | (43.5) | % | |||||||||||||||||||||||||||||||
| Non-GAAP Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||
| Intangible asset amortization | — | — | — | — | (158,903) | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Share-based compensation expense | (4,427) | 0.5 | (46,120) | (19,643) | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Acquisition accounting inventory fair value step-up | (37,794) | 3.7 | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Income tax effect of above adjustments | — | — | — | — | — | — | 57,477 | 43.4 | |||||||||||||||||||||||||||||||||||||||
| Total of non-GAAP adjustments | (42,221) | 4.2 | (46,120) | (19,643) | (158,903) | — | 57,477 | 43.4 | |||||||||||||||||||||||||||||||||||||||
| Non-GAAP Adjusted | $ | 86,492 | 91.6 | % | $ | 323,167 | $ | 220,857 | $ | — | $ | 51,256 | $ | (435) | (0.1) | % | |||||||||||||||||||||||||||||||
12
JAZZ PHARMACEUTICALS PLC
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION - CERTAIN LINE ITEMS
(In thousands, except percentages)
(Unaudited)
| Year ended December 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cost of product sales | Gross margin | SG&A | R&D | Intangible asset amortization | Acquired IPR&D | Interest expense, net | Income tax benefit | Effective tax rate | |||||||||||||||||||||||||||||||||||||||||||||
| GAAP Reported | $ | 503,296 | 87.5 | % | $ | 1,809,271 | $ | 782,736 | $ | 654,661 | $ | 947,862 | $ | 195,051 | $ | (272,443) | 43.4 | % | |||||||||||||||||||||||||||||||||||
| Non-GAAP Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible asset amortization | — | — | — | — | (654,661) | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation expense | (18,031) | 0.5 | (186,622) | (86,480) | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
| Integration related expenses | (1,301) | — | (19,394) | (9,611) | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
| Acquisition accounting inventory fair value step-up | (147,948) | 3.6 | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
| Income tax effect of above adjustments | — | — | — | — | — | — | — | 245,976 | (48.7) | ||||||||||||||||||||||||||||||||||||||||||||
| Total of non-GAAP adjustments | (167,280) | 4.1 | (206,016) | (96,091) | (654,661) | — | — | 245,976 | (48.7) | ||||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP Adjusted | $ | 336,016 | 91.6 | % | $ | 1,603,255 | $ | 686,645 | $ | — | $ | 947,862 | $ | 195,051 | $ | (26,467) | (5.3) | % | |||||||||||||||||||||||||||||||||||
| Year ended December 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cost of product sales | Gross margin | SG&A | R&D | Intangible asset amortization | Acquired IPR&D | Interest expense, net | Income tax expense (benefit) | Effective tax rate | |||||||||||||||||||||||||||||||||||||||||||||
| GAAP Reported | $ | 445,713 | 88.3 | % | $ | 1,385,294 | $ | 884,000 | $ | 627,313 | $ | 10,000 | $ | 238,097 | $ | (91,429) | (19.4) | % | |||||||||||||||||||||||||||||||||||
| Non-GAAP Adjustments: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible asset amortization | — | — | — | — | (627,313) | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation expense | (14,802) | 0.5 | (158,570) | (74,673) | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
| Acquisition accounting inventory fair value step-up | (135,014) | 3.5 | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
| Income tax effect of above adjustments | — | — | — | — | — | — | — | 218,522 | 28.0 | ||||||||||||||||||||||||||||||||||||||||||||
| Total of non-GAAP adjustments | (149,816) | 4.0 | (158,570) | (74,673) | (627,313) | — | — | 218,522 | 28.0 | ||||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP Adjusted | $ | 295,897 | 92.3 | % | $ | 1,226,724 | $ | 809,327 | $ | — | $ | 10,000 | $ | 238,097 | $ | 127,093 | 8.6 | % | |||||||||||||||||||||||||||||||||||
13
JAZZ PHARMACEUTICALS PLC
RECONCILIATION OF 2026 GAAP TO NON-GAAP GUIDANCE MEASURES
| Projected Range | |||||||||||
| (In millions, except percentages) | Low | High | |||||||||
| GAAP gross margin on total revenues | 89% | 90% | |||||||||
| Acquisition accounting inventory fair value step-up | 1% | 1% | |||||||||
| Non-GAAP gross margin on total revenues | 90% | 91% | |||||||||
| GAAP SG&A expenses | $ | 1,424 | $ | 1,497 | |||||||
| Share-based compensation expense | (164) | (177) | |||||||||
| Non-GAAP SG&A expenses | $ | 1,260 | $ | 1,320 | |||||||
| GAAP R&D expenses | $ | 811 | $ | 867 | |||||||
| Share-based compensation expense | (86) | (92) | |||||||||
| Non-GAAP R&D expenses | $ | 725 | $ | 775 | |||||||
| GAAP effective tax rate | 0% | 10% | |||||||||
| Income tax effect of GAAP to non-GAAP reconciling items | 11.5% | 3.5% | |||||||||
| Non-GAAP effective tax rate | 11.5% | 13.5% | |||||||||
Contacts:
Investors:
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
14
FAQ
How did Jazz Pharmaceuticals (JAZZ) perform financially in 2025?
Jazz Pharmaceuticals grew 2025 total revenues to $4.27 billion, up 5% year over year. Fourth-quarter revenue reached $1.20 billion, up 10%. Growth was led by Xywav, Epidiolex/Epidyolex, and oncology products, despite a GAAP net loss from large R&D and legal charges.
What were Jazz Pharmaceuticals’ key product drivers in 2025?
The main 2025 growth drivers were Xywav with $1.66 billion in sales (+12%) and Epidiolex/Epidyolex with $1.06 billion (+9%). Oncology net product sales were $1.13 billion, supported by Modeyso, Ziihera, and Zepzelca, helping sustain overall revenue momentum.
Why did Jazz Pharmaceuticals report a GAAP net loss in 2025?
Jazz reported a $356 million GAAP net loss in 2025 versus $560 million income in 2024 mainly due to $947.9 million of acquired in‑process R&D from the Chimerix deal and significant Xyrem and Avadel litigation settlements impacting SG&A expenses.
What was Jazz Pharmaceuticals’ 2025 non-GAAP adjusted earnings?
Non-GAAP adjusted net income in 2025 was $521.9 million with non-GAAP EPS of $8.38. These figures exclude items such as intangible amortization, share-based compensation, acquisition-related inventory step-up, integration costs, and acquired in‑process R&D, plus related tax effects.
What 2026 financial guidance did Jazz Pharmaceuticals provide?
For 2026, Jazz guided total revenues of $4.25–$4.50 billion. It expects GAAP gross margin of 89–90% and non-GAAP gross margin of 90–91%, with non-GAAP SG&A of $1.26–$1.32 billion and non-GAAP R&D of $725–$775 million.
How strong is Jazz Pharmaceuticals’ cash flow and balance sheet?
In 2025, Jazz generated $1.36 billion of cash from operations. As of December 31 2025, it held $2.44 billion in cash, cash equivalents and investments, had $5.36 billion in long-term debt principal outstanding, and maintained $885 million of undrawn revolver capacity.
Filing Exhibits & Attachments
4 documents
Jazz Pharmaceuticals Plc
NASDAQ:JAZZ
JAZZ Rankings
JAZZ Latest News
JAZZ Latest SEC Filings
Feb 27, 2026
[144] Jazz Pharmaceuticals plc SEC Filing
Feb 26, 2026
[144] Jazz Pharmaceuticals plc SEC Filing
Feb 26, 2026
[144] Jazz Pharmaceuticals plc SEC Filing
Feb 24, 2026
[10-K] Jazz Pharmaceuticals plc Files Annual Report